Date: 2017-03-28
Type of information: R&D agreement
Compound: human stem cell lines
Company: Plasticell (UK) Agency for Science, Technology and Research (A*STAR) (Singapore) Nanyang Technological University (Singapore)
Therapeutic area:
Type agreement: research - R&D - licensing
Action mechanism: cell therapy
Disease:
Details: • On March 28, 2017, Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University to progress its therapeutic stem cell pipeline. The agreements encompass technology licensing, collaborative research and scientific exchange visits. Plasticell will initially collaborate with the laboratories of Prof. Peter Dröge (School of Biological Sciences, NTU) and Dr. Farid Ghadessy (p53Lab, A*STAR) to apply proprietary genome editing technology to insert functional multi-transgene cassettes into specific loci of human stem cell lines. The engineered lines will be used by Plasticell in multiple projects focused on precisely directed stem cell differentiation, phenotypic screening for drug discovery and in next-generation immuno-oncology applications.
Financial terms:
Latest news:
